Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
VentriPoint Diagnostics ( (TSE:VPT) ) has issued an announcement.
Ventripoint Diagnostics has signed a memorandum of understanding and consulting agreement with LG Consulting Solutions to support commercialization and deployment of its VMS+ AI-enhanced echocardiography system in Northern California. LG Consulting will purchase a VMS+ unit as a demonstration and implementation platform and work with cardiac programs in markets such as Sacramento and San Francisco to evaluate clinical performance and economic value.
Under the deal, LG Consulting will provide economic analysis, business case development, implementation planning, and ongoing operational support to help hospitals assess the impact of integrating VMS+ into cardiac care pathways. The agreement also includes a potential revenue-sharing component tied to 3D echocardiography processing services, positioning Ventripoint to deepen its presence in a region with a high concentration of leading cardiac centers and potentially accelerating broader adoption of its technology.
The most recent analyst rating on (TSE:VPT) stock is a Hold with a C$0.12 price target. To see the full list of analyst forecasts on VentriPoint Diagnostics stock, see the TSE:VPT Stock Forecast page.
Spark’s Take on TSE:VPT Stock
According to Spark, TipRanks’ AI Analyst, TSE:VPT is a Neutral.
The score is held back primarily by weak financial fundamentals (ongoing losses, cash burn, and negative equity). Technicals are moderately constructive with improving momentum, and corporate updates are directionally positive, but valuation support is limited due to negative earnings and no dividend indicated.
To see Spark’s full report on TSE:VPT stock, click here.
More about VentriPoint Diagnostics
Ventripoint Diagnostics Ltd. is a medical technology company specializing in the application of artificial intelligence to echocardiography for cardiac assessment. Its VMS and VMS+ systems use proprietary knowledge-based reconstruction to deliver MRI-equivalent volumetric heart measurements from standard ultrasound, and are approved for use with all major ultrasound vendors in the U.S., Europe and Canada.
Average Trading Volume: 147,184
Technical Sentiment Signal: Strong Sell
Current Market Cap: C$20.61M
For an in-depth examination of VPT stock, go to TipRanks’ Overview page.